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both direct retroviral gene transfer as well as adenoviral gene 
transfer. 
During vascular isolation, we first injected a concentrated 
solution ofa retroviral vector containing human heat-stable alkaline 
phosphatase into skeletal muscle 4 days after lidocaine-induced 
regeneration and angiogenesis. In these experiments we docu- 
mented a substantially higher expression of recombinant protein 
than that achieved using the previously described technique of 
cell-mediated gene therapy. Recombinant gene expression was 
observed in both the muscle and capillary endothelium. 
This technique of vascular isolation of the hind limb has also 
been used to test the transduction efficiency of adenoviral vectors. 
Current gene therapy strategies using adenoviralvectors targeted to 
the lung or liver have been complicated by an inflammatory 
response and an associated tissue injury. We hypothesized that 
adenoviral transduction ofrat skeletal muscle capillary bed during 
vascular isolation would produce gene transfer sufficient to achieve 
systemic levels of a recombinant protein without tissue injury. 
During vascular isolation, rats received a replicationqncompetent 
adenovirus (Ad) encoding for either the marker gene, human 
placental alkaline phosphatase (hpAP) or interleukin-1 receptor 
antagonist (IL-lra), an antagonist oflL-1 mediated isease. Gene 
transfer over a 109 × 1012 particle/mL range to the gastrocnemius 
capillary endothelium and muscle fibers was highly efficient and 
titer dependent, reaching a maximum transduction rate in these 
tissues of 71% + 7% and 25% _+ 5%, respectively, 5 days after gene 
transfer. Adenoviral-induced inflammation i skeletal muscle was 
not observed, and distant organ transfer was minimal or absent. 
Gastrocnemius muscle from rats given Ad-IL-lra had 241 i 66 pg 
IL- l ra/mg protein, whereas the Ad-hpAp negative control had 
35 _+ 14 pg ILq-ra /mg protein. More importantly-, in the Ad-IL- 
lra transduced rats, a serum level of 185 _+ 20 pg/mL IL-lra was 
documented. Athymic rats given Ad-IL-lra had serum levels of 
4:93 _+ 62 pg/mL IL-lra 14 days after transduction, an IL-lra was 
detected for up to 98 days. Serum from Ad-IL-lra athymic rats 
significantly inhibited IL-1 [3-induced (1 ng/mL) PGE 2 produc- 
tion from cultured endothelial cells by 82% -+ 2%. Thus this gene 
transfer strategy results in substantial transduction ofendothelinm 
and muscle fibers, sufficient o achieve pharmacologic levels of 
IL-lra, without evidence of tissue injury. 
We believe the capillary bed of skeletal muscle continues to 
hold considerable promise as a technique of somatic gene therapy 
to deliver ecombinant proteins to the systemic irculation, such as 
human factor VIII or IX deficiency in hemophiliacs or for the 
purposes of treating vascular diseases uch as the induction of 
angiogenesis in a chronic ischemic limb. 
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CELL-BASED GENE TRANFER 
IN  B IOMATERIALS  
A number of biomaterials in a wide variety of configurations and 
materials have been adapted to gene transfer technology. Special 
needs uch as immunoisolation, size of the gene product molecule, 
biodegradability, cell carrying capacity, and durability both of the 
material and gene expression determine physical characteristics. 
Hollow fibers, pillows, and microspheres are commonly used. With 
a single gene the null mutant apolipoprotein deficicnt (knockout) 
mouse converts aspecies highly resistant to atherosclerosis to one 
that is highly susceptible. This mutant model develops evere 
atherosclerosis on a normal diet. The lesions closely resemble 
human lesions. 
Using a plasmid containing the eDNA encoding apo E, 
fibroblasts or mouse mammary tumor cells, and two constructs: (1) 
retroviral vectors based on LNL6 retroviral vector (MoMLV), the 
long terminal repeat promoter (LTR) and one of several enhancers; 
or (2) a recombinant bovine paplllomavirus expression vector 
containing a mouse metallothionein I promoter, the human 
metallothionein IA gene and, in both, the human apo E gene, we 
have been able to transfect the fibroblasts and mouse mammary 
tumor cells, load the cells into the devices named above, and obtain 
apo E expression both in tissue culture and in the plasma of mice 
into the cell-loaded evices implanted. Coincident with the appear- 
ance of apo E in the mouse plasma was a substantial reduction in 
serum cholesterol and triglycerides. Inhibition of atherosderosis 
throughout the aorta of the apo E-deficient mouse was prominent 
in the treated mouse compared with the untreated control, (28% vs 
69%, respectively, based on planimetric measurement of he lesions 
visible on the surface of the aortas). 
This is an excellent animal model in which to study athero- 
genesis and its progression and regression. As far as therapeutic 
potential, there are several obstacles and pitfalls, including a low 
level of transfected gene expression, eventual loss of gene expres- 
sion, need for continuing replication of the transfected cells, escape 
of implanted cells from the device, induction of host viremia, and 
unpredictable consequences of random gene insertion. 
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SMOOTH MUSCLE CELLS FOR SYSTEMIC AND 
LOCAL THERAPY 
Smooth muscle cells are an excellent target for vascular gene 
transfer because they have many properties that make them a 
reliable and durable vector. They are the principle cellular compo- 
nent of large arteries and veins and participate invarious important 
vascular disease states, including atherosclerosis and intimal hyper- 
plasia, after vascular econstruction. The cells are readily cultured 
and, as we have shown, can be seeded back in vivo. These seeded 
cells, like their endogenous relatives, are long-lived. We have used 
vascular smooth muscle cells transduced with replication-defective 
rettovirus as a means for transferring genes into blood vessels for 
three purposes: (1) systemic gene therapy; (2) local pharmacology 
to control vascular function; and (3) the development of models of 
vascular disease. This method of transferring genes leads to stable, 
long-term expression of the vitally encoded protein because the 
transferred gene is incorporated into the host genome. A significant 
weakness in this approach is that cell culture and subsequent 
seeding back into the artery are required for efficient gene transfer. 
Because transduction with these vectors i  so poor in vivo (approxi- 
mately 1in 10,000 cells), the only efficient way to transfer the gene 
of interest isto transduce the cells in vitro and then to transfer the 
cells to the vascular site. The cells are placed into a discrete portion 
of the vasculature (e.g., an injured artery or a graft) and can be 
removed later by surgical excision, la Although there has been 
neither detectable helper virus activity nor evidence of neoplastic 
transformation in the smooth muscle cells we have studied in vivo, 
it is reassuring to have a practical means to deal with the problem 
should the need arise. 
The expression ofthe transferred gene is controlled at the level 
of transcription by the retroviral LTRs and is continuous and not 
regulatable. This limitation of the system isnot of great significance 
because the clinical problem isto obtain adequate expression ofthe 
transferred gene and not to suppress overexpression. Nevertheless, 
in the future we hope to have mechanisms for the control of the 
expression of the transferred gene. 
Systemic gene therapy 
Most of our studies have been performed insyngeneic Fischer 
344 rats using retroviral vectors developed by Miller and col- 
leagues. 1'4 These retroviral vectors do not contain the necessary 
components o encode for the coat proteins and therefore are 
replication-defective. The regulatory elements (LTRs) remain, and 
the gene of interest ogether with a selectable marker such as 
neomycin phosphotransferase (NEO) are inserted. The complete 
vector is generated bytransfecting the retroviral plasmid containing 
the gene of interest into a "packaging line" that provides the 
necessary proteins for encapsulating the genetic material. The viral 
particles generated in this manner act as one-way shuttles to infect 
vascular smooth muscle cells. As noted above, they are not capable 
of replication. In the initial experiments, he Fischer 344 rat smooth 
muscle cells were infected with retrovirus encoding either E. coli 
beta galactosidase (13 gal) or human placental alkaline phos- 
phatase. 1'~ The transduced cells are selected inthe neomycin analog 
G418. The cells stably expressing either [3 gal or alkaline phos- 
phatase are then seeded into rat carotid arteries denuded of 
endothelinm by the passage of a balloon catheter. The smooth 
muscle cells stick in regions lacking endothelinm within 15 minutes 
and remain after the circulation isrestored. Three major issues have 
been addressed. First, it appears that the cultured smooth muscle 
ceils are robust and can survive culture, retroviral infection, and 
harsh selection in vitro and still survive long term in the in vivo 
environment. Second, these cells infected with retrovirus do not 
appear to be transformed. They replicated for one or two rounds in 
the neointima nd then resume quiescence in a manner similar to 
the endogenous cells. An intima formed by seeded ceils reaches 
maximal thickness between 2 and 4 weeks after surgery and does 
not change thereafter up to 1 year. Third, the expression of the 
transferred genes appears to be durable. We have evaluated the 
expression ofa number of human and animal genes ([3 gal, human 
alkaline phosphatase, human adenosine deaminase, baboon tissue 
inhibitor of metalloproteinases-1 [TIMP-1], rat erythropoietin), 
and have found that he encoded proteins are expressed and active, 
although in some circumstances animmunologic response to the 
expressed protein has been observed (for example, to baboon 
TIMP-1). 
We have been able to demonstrate recently that the encoded 
protein can have a systemic impact. In rats seeded with smooth 
muscle cells encoding rat erythropoietin, the hematocrit levels rise 
from 45% to 60% over a period of several weeks even though 
endogenous erythropoietin expression is suppressed in these ani- 
mals. Although this systemic effect can be obtained with relatively 
few cells (approximately 10,000 to 50,000 ceils per carotid artery), 
a note ofcantion isin order. Erythropoietin is an extremely potent 
hormone, and a very small amount produces a dramatic response. 
Either more effective vectors or larger numbers of smooth muscle 
cells would be required to achieve xpression of a protein in the 
microgram-per-milliliter range. 
Models of vascular disease 
We are currently using the smooth muscle ceil-based transfer 
approach to model certain aspects of atherosclerosis. One of the 
interesting properties of atherosclerotic plaques, but not of rat 
intimal thickening, is the pronounced thrombotic activity that can 
be observed when the luminal surface is disrupted. The reason for 
this response in far-advanced atherosderotic plaques is not yet 
evident. Some investigators have proposed that the thrombotic 
activity is attributable toabnormal location and expression of two 
genes, tissue factor and plasminogen activator-1 (PAL1), in the 
plaque. Because thrombosis i  not a property of rat neointima, we 
are currently attempting tomodel human thrombosis by introduc- 
ing smooth muscle cells that overexpress either tissue factor or 
PAL1. The preliminary data support he conclusion that these 
genes may have a dramatic effect on local vascular thrombosis. 
Local pharmacology 
It would be highly dcsirable to control stenosis locally and 
avoid the systemic cffccts of the administered drug. We are 
currently using the smooth muscle cell-based gene transfer ap- 
proach to develop harmacologic strategies for controlling intimal 
hyperplasia and stenosis or restenosis after vascular surgery. In our 
initial experiments, wehave focused on the role of matrix metallo- 
proteinases in smooth muscle cell proliferation and migration and 
the development of the neointima. We have observed that two 
matrix metalloproteinases (72kD and 92kD gelatinases; MMP2 
and 9) are expressed and active in the balloon-injured rat carotid 
artery. Although the systemic administration f drugs that affect 
the active site inhibits inrimal thickening, these drugs have a toxic 
